Table 4.
Colorectal cancer characteristics comparing BRAFV600E-CRCs and BRAFwt-CRCs
| Total | BRAFV600E-CRC | BRAFwt-CRC | P valuea | |
| Cohort size; n (%) | 43 (100) | 21 (48.8) | 22 (51.2) | |
| CRC location; n (%) | <0.001 | |||
| Proximal | 22 (51.2) | 17 (81.0) | 5 (22.7) | |
| Distal | 21 (48.8) | 4 (19.0) | 17 (77.3) | |
| Median CRC diameter in mm; n (range) | 32.5 (16.8–51.2) | 35 (15.5–55) | 25 (20–50) | .820 |
| Tumor stage; n (%) | .586 | |||
| Nonadvanced | 29 (67.4) | 15 (71.4) | 14 (63.6) | |
| Advanced | 14 (32.6) | 6 (28.6) | 8 (36.4) | |
| MLH1 expression loss; n (% of cohort) | 10 (23.2) | 10 (47.6) | 0 | <0.001 |
| PMS2 expression loss; n (% of cohort) | 10 (23.2) | 10 (47.6) | 0 | <0.001 |
| MSH2 expression loss | 0 | 0 | 0 | NA |
| MSH6 expression loss | 0 | 0 | 0 | NA |
| SMAD4 expression loss | 4 | 2 (9.5) | 2 (9.1) | 1.000 |
| p53 overexpression/loss of expressionb | 22 | 9 (42.9) | 17 (77.3) | 0.475 |
| MLH1 deficient | 1 (33.3) | 1 (4.8) | 0 | |
| MLH1 proficient | 21 (66.7) | 8 (38.1) | 17 (77.3) | |
| p16 expression loss | 2 | 2 (9.5) | 0 | 0.163 |
| RAS mutation | NA | NA | 8 (36.4) | NA |
| KRAS | 7 (31.8) | |||
| NRAS | 1 (4.5) | |||
| TP53 mutation | NA | NA | 9 (40.9) | NA |
| PIK3CA mutation | NA | NA | 4 (18.2) | NA |
| SMAD4 mutation | NA | NA | 2 (9.1) | NA |
CRC, colorectal cancer; IQR, interquartile range.
a
Comparing BRAFV600E-CRC and BRAFwt-CRC with χ2 statistics for categorical variables and Mann-Whitney U test for continuous variables.
b
Based on 34 CRCs.